Cencora, Inc. (NYSE:COR) Given Average Recommendation of "Moderate Buy" by Brokerages

Cencora, Inc. (NYSE:COR - Get Free Report) has earned a consensus recommendation of "Moderate Buy" from the ten analysts that are presently covering the firm, MarketBeat reports. Two research analysts have rated the stock with a hold recommendation and eight have assigned a buy recommendation to the company. The average 12 month price target among brokers that have issued ratings on the stock in the last year is $277.90.

COR has been the topic of a number of research reports. Evercore ISI upped their price target on shares of Cencora from $270.00 to $280.00 and gave the company an "outperform" rating in a research note on Thursday, February 6th. Wells Fargo & Company upped their price target on shares of Cencora from $237.00 to $251.00 and gave the company an "equal weight" rating in a research note on Wednesday, January 29th. UBS Group upped their price target on shares of Cencora from $275.00 to $285.00 and gave the company a "buy" rating in a research note on Thursday, November 7th. Mizuho initiated coverage on shares of Cencora in a research report on Wednesday, December 4th. They set an "outperform" rating and a $280.00 target price on the stock. Finally, Barclays increased their target price on shares of Cencora from $263.00 to $290.00 and gave the stock an "overweight" rating in a research report on Thursday, November 7th.

Insider Activity at Cencora

In other news, CEO Robert P. Mauch sold 4,970 shares of the firm's stock in a transaction on Monday, March 3rd. The shares were sold at an average price of $255.00, for a total transaction of $1,267,350.00. Following the completion of the transaction, the chief executive officer now owns 51,070 shares of the company's stock, valued at approximately $13,022,850. This trade represents a 8.87 % decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through the SEC website. Also, EVP Silvana Battaglia sold 1,678 shares of the firm's stock in a transaction on Friday, December 20th. The shares were sold at an average price of $228.72, for a total transaction of $383,792.16. Following the transaction, the executive vice president now directly owns 20,329 shares of the company's stock, valued at $4,649,648.88. The trade was a 7.62 % decrease in their position. The disclosure for this sale can be found here. Insiders sold a total of 11,648 shares of company stock valued at $2,862,342 in the last quarter. Insiders own 10.80% of the company's stock.

Hedge Funds Weigh In On Cencora

Several large investors have recently modified their holdings of COR. Swedbank AB increased its position in shares of Cencora by 2.3% during the third quarter. Swedbank AB now owns 1,394,449 shares of the company's stock worth $313,863,000 after buying an additional 31,104 shares during the period. Harbor Capital Advisors Inc. acquired a new stake in shares of Cencora during the third quarter worth $62,000. Intact Investment Management Inc. acquired a new stake in shares of Cencora during the third quarter worth $70,000. National Pension Service increased its position in shares of Cencora by 16.8% during the third quarter. National Pension Service now owns 307,919 shares of the company's stock worth $69,306,000 after buying an additional 44,346 shares during the period. Finally, QRG Capital Management Inc. increased its position in shares of Cencora by 1.8% during the third quarter. QRG Capital Management Inc. now owns 20,020 shares of the company's stock worth $4,506,000 after buying an additional 351 shares during the period. Institutional investors own 97.52% of the company's stock.

Cencora Stock Performance

Shares of COR stock traded down $1.88 on Wednesday, reaching $251.40. The stock had a trading volume of 1,520,486 shares, compared to its average volume of 1,505,621. The company has a quick ratio of 0.54, a current ratio of 0.92 and a debt-to-equity ratio of 16.40. The firm's 50-day moving average is $242.78 and its two-hundred day moving average is $238.09. The firm has a market capitalization of $48.75 billion, a price-to-earnings ratio of 35.76, a P/E/G ratio of 1.31 and a beta of 0.49. Cencora has a 12 month low of $214.77 and a 12 month high of $262.26.

Cencora (NYSE:COR - Get Free Report) last issued its earnings results on Wednesday, February 5th. The company reported $3.73 earnings per share (EPS) for the quarter, beating analysts' consensus estimates of $3.50 by $0.23. Cencora had a net margin of 0.46% and a return on equity of 328.62%. On average, research analysts expect that Cencora will post 15.37 EPS for the current fiscal year.

Cencora Dividend Announcement

The business also recently disclosed a quarterly dividend, which was paid on Monday, March 3rd. Investors of record on Friday, February 14th were paid a $0.55 dividend. This represents a $2.20 annualized dividend and a yield of 0.88%. The ex-dividend date was Friday, February 14th. Cencora's payout ratio is 31.29%.

About Cencora

Cencora, Inc sources and distributes pharmaceutical products. The company's U.S. Healthcare Solutions segment distributes pharmaceuticals, over-the-counter healthcare products, home healthcare supplies and equipment, and related services to acute care hospitals and health systems, independent and chain retail pharmacies, mail order pharmacies, medical clinics, long-term care and alternate site pharmacies, and other customers; provides pharmacy management, staffing, and other consulting services; supply management software to retail and institutional healthcare providers; packaging solutions to various institutional and retail healthcare providers; clinical trial support, product post-approval, and commercialization support services; data analytics, outcomes research, and additional services for biotechnology and pharmaceutical manufacturers; pharmaceuticals, vaccines, parasiticides, diagnostics, micro feed ingredients, and other products to the companion animal and production animal markets; and sales force services to manufacturers.